Is Toxoplasmosis a risk factor in diabetic patients in Tehran?

Document Type : Original Research

Authors
Parasitology Department, Medical Sciences Faculty, Tarbiat Modares University, Tehran, Iran.
Abstract
Aims: Toxoplasmosis is a cosmopolitan zoonotic disease caused by an obligate apicomplexan intracellular parasite known as Toxoplasma gondii (T. gondii). Recently, toxoplasmosis has been suggested as a risk factor for diabetes. Thus, the present study aimed to assess the association between T. gondii infection and two types of diabetes in Tehran, the capital of Iran.

Materials & Methods: In the current cross-sectional study, 98, 95, and 94 blood samples were collected from Type 1 and Type 2 diabetic and nondiabetic individuals, referring to Imam Sajad hospital from February to August 2018, respectively. Anti-T. gondii specific IgG and IgM antibodies were measured using enzyme-linked immunosorbent assay (ELISA). Moreover, a structured demographic questionnaire was completed for each person.

Results: IgG antibody was found to be positive in 16.32 (16 of 98) and 57.89% (55 of 95) of patients with diabetes Type 1 and Type 2 and 17.02% (16 of 94) of nondiabetic individuals as controls, respectively. However, the prevalence of positive IgM antibody in these groups was determined as 2.04 (2 of 98), 6.32 (6 of 95), and 17.02 % (16 of 94), respectively.

Conclusion: This finding revealed that toxoplasmosis could be considered as a possible risk factor for diabetes Type 2, while no statistically significant association was found between T. gondii infection and diabetes Type 1. More research is required to be conducted in the future in order to better understand this association.

Keywords

Subjects


1. Dalimi A, Abdoli A. Latent toxoplasmosis and human. Iranian journal of parasitology. 2012;7(1):1.
2. Dubey J. Toxoplasmosis–a waterborne zoonosis. Veterinary parasitology. 2004;126(1-2):57-72.
3. Daryani A, Sarvi S, Aarabi M, Mizani A, Ahmadpour E, Shokri A, Rahimi M-T, Sharif M. Seroprevalence of Toxoplasma gondii in the Iranian general population: a systematic review and meta-analysis. Acta tropica. 2014;137:185-94.
4. Saadatnia G, Golkar M. A review on human toxoplasmosis. Scandinavian journal of infectious diseases. 2012;44(11):805-14.
5. Torgerson PR, Mastroiacovo P. The global burden of congenital toxoplasmosis: a systematic review. Bulletin of the World Health Organization. 2013;91:501-8.
6. Flegr J, Preiss M, Klose J, Havlı́ček J, Vitáková M, Kodym P. Decreased level of psychobiological factor novelty seeking and lower intelligence in men latently infected with the protozoan parasite Toxoplasma gondii Dopamine, a missing link between schizophrenia and toxoplasmosis? Biological psychology. 2003;63(3):253-68.
7. Foroutan-Rad M, Khademvatan S, Majidiani H, Aryamand S, Rahim F, Malehi AS. Seroprevalence of Toxoplasma gondii in the Iranian pregnant women: a systematic review and meta-analysis. Acta tropica. 2016;158:160-9.
8. Sutterland A, Fond G, Kuin A, Koeter M, Lutter R, Van Gool T, Yolken R, Szoke A, Leboyer M, De Haan L. Beyond the association. T oxoplasma gondii in schizophrenia, bipolar disorder, and addiction: systematic review and meta‐analysis. Acta Psychiatrica Scandinavica. 2015;132(3):161-79.
9. Canivell S, Gomis R. Diagnosis and classification of autoimmune diabetes mellitus. Autoimmunity reviews. 2014;13(4-5):403-7.
10. Filippi CM, von Herrath MG. Viral trigger for type 1 diabetes: pros and cons. Diabetes. 2008;57(11):2863-71.
11. Jeon CY, Haan MN, Cheng C, Clayton ER, Mayeda ER, Miller JW, Aiello AE. Helicobacter pylori infection is associated with an increased rate of diabetes. Diabetes care. 2012;35(3):520-5.
12. Beshay EVN, El-Refai SA, Helwa MA, Atia AF, Dawoud MM. Toxoplasma gondii as a possible causative pathogen of type-1 diabetes mellitus: evidence from case-control and experimental studies. Experimental parasitology. 2018;188:93-101.
13. Goekce C, Yazar S, Bayram F, GÜNDOĞAN K. Toxoplasma gondii antibodies in type 1 diabetes mellitus. Turkiye Klinikleri Journal of Medical Sciences. 2008;28(5):619-22.
14. Kanková S, Flegr J, Calda P. An elevated blood glucose level and increased incidence of gestational diabetes mellitus in pregnant women with latent toxoplasmosis. Folia parasitologica. 2015;62:1.
15. Khalil M, Baothman M, Alserhan F, Almunyif A, Alsharbe G, Samaren H, Deqnah N, Al Malki A, Al Harbi W. Prevalence of Toxoplasma gondii infection in diabetic patients in Makkah AL Mukarramah, Saudi Arabia. Tropical Biomedicine. 2018;35(2):464-71.
16. Khattab HM, El Bassiouni SO, Abuelela MH, Elsalam DOA. Seroprevalence of Toxoplasma gondii among a group of Egyptian patients with type I diabetes mellitus. Bulletin of the National Research Centre. 2019;43(1):20.
17. Prandota J. T. gondii infection acquired during pregnancy and/or after birth may be responsible for development of both type 1 and 2 diabetes mellitus. J Diabetes Metab. 2013;4(2):55.
18. Saeed SA, Al-Aubaidi IK. Seroprevalence of Toxoplasmosis Antibodies among Diabetes Mellitus Patients and Assessment some Biochemical Markers. Ibn AL-Haitham Journal For Pure and Applied Science. 2018:539-51.
19. Abdoli A, Dalimi A, Movahedin M. Impaired reproductive function of male rats infected with Toxoplasma gondii. Andrologia. 2012;44:679-87.
20. Molan A, Nosaka K, Hunter M, Wang W. A systemic review and meta-analysis of human case -control studies examining the association between Toxoplasma gondii and type 2 diabetes mellitus. American Journal of Life Science Researches. 2018;6(3):106-22.
21. Majidiani H, Dalvand S, Daryani A, Galvan-Ramirez MdlL, Foroutan-Rad M. Is chronic toxoplasmosis a risk factor for diabetes mellitus? A systematic review and meta-analysis of case-control studies. Brazilian Journal of Infectious Diseases. 2016;20(6):605-9.
22. Shirbazou S, Delpisheh A, Mokhetari R, Tavakoli G. Serologic detection of anti Toxoplasma gondii infection in diabetic patients. Iranian Red Crescent medical journal. 2013;15(8):701.
23. Modrek MJ, Saravani R, Mousavi M, Khorashad AS, Piri M. Investigation of IgG and IgM antibodies against Toxoplasma gondii among diabetic patients. International Journal of Infection. 2015;2(3).
24. Saki J, Shafieenia S, Foroutan-Rad M. Seroprevalence of toxoplasmosis in diabetic pregnant women in southwestern of Iran. Journal of parasitic diseases. 2016;40(4):1586-9.
25. Hemida MH, Shahat SA, Bayoumy AM, Mohamed KA, Hassan SM. Toxoplasmosis prevalence in Egyptian diabetic patients. Al-Azhar Assiut Medical Journal. 2018;16(2):113.
26. Khalili M, Mahami-Oskouei M, Shahbazi A, Safaiyan A, Mohammadzadeh-Gheshlaghi N, Mahami-Oskouei L. The Correlation between Serum Levels of Anti-Toxoplasma gondii Antibodies and the Risk of Diabetes. Iranian journal of parasitology. 2018;13(4):637.
27. Siyadatpanah A, Tabatabaie F, Oormazdi H, Meamar A, Razmjou E, Hadighi R, Akhlaghi L. Comparison of anti-Toxoplasma IgG and IgM antibodies determined by ELISA method in diabetic and non-diabetic individuals in west Mazandaran province, Iran, 2011-2012. Ann Biol Res. 2013;4(6):281-5.
28. Alvarado-Esquivel C, Loera-Moncivais N, Hernandez-Tinoco J, Sanchez-Anguiano LF, Hernandez-Madrid G, Rabago-Sanchez E, Centeno-Tinoco MM, Sandoval-Carrillo AA, Salas-Pacheco JM, Campos-Moreno OV. Lack of association between Toxoplasma gondii infection and diabetes mellitus: a matched case-control study in a mexican population. Journal of clinical medicine research. 2017;9(6):508.
29. Younis EZ, Elamami AH, Almnefy ME, Alsherif NA, Laraibe HA, Burnia AI. Anti-Toxoplasma gondii IgG, Ig M, and IgA among Type 2 diabetic Patients in Benghazi, Libya. A Comparison Study. Journal of Immunology and Microbiology. 2018;2(2):2.
30. Li Y-X, Xin H, Zhang X-Y, Wei C-Y, Duan Y-H, Wang H-F, Niu H-T. Toxoplasma gondii infection in diabetes mellitus patients in China: Seroprevalence, risk factors, and case-control studies. BioMed research international. 2018;2018.
31. Chagas CEA, Borges MC, Martini LA, Rogero MM. Focus on vitamin D, inflammation and type 2 diabetes. Nutrients. 2012;4(1):52-67.
32. Pradhan A. Obesity, metabolic syndrome, and type 2 diabetes: inflammatory basis of glucose metabolic disorders. Nutrition reviews. 2007;65(suppl_3):S152-S6.
33. Ramadan JW, Steiner SR, O’Neill CM, Nunemaker CS. The central role of calcium in the effects of cytokines on beta-cell function: implications for type 1 and type 2 diabetes. Cell calcium. 2011;50(6):481-90.
34. Oz HS. Toxoplasmosis, pancreatitis, obesity and drug discovery. Pancreatic disorders & therapy. 2014;4(2).
35. Carter C. Toxoplasmosis and polygenic disease susceptibility genes: extensive Toxoplasma gondii host/pathogen interactome enrichment in nine psychiatric or neurological disorders. Journal of pathogens. 2013;2013:29.
36. Reeves GM, Postolache TT, Mazaheri S, Snitker S, Langenberg P, Giegling I, Hartmann A, Konte B, Friedl M, Okusaga O. A positive association between T. gondii seropositivity and obesity. Frontiers in public health. 2013;1:73.
37. Oz HS, Tobin T. Atovaquone ameliorate gastrointestinal toxoplasmosis complications in a pregnancy model. Medical science monitor: international medical journal of experimental and clinical research. 2012;18(9):BR337.
38. Han Y, Nie L, Ye X, Zhou Z, Huang S, Zeng C, Guo C, Ou M, Xiao D, Zhang B. The association between Toxoplasma gondii infection and hypertensive disorders in T2DM patients: a case-control study in the Han Chinese population. Parasitology research. 2018;117(3):689-95.
39. Krause I, Anaya JM, Fraser A, Barzilai O, Ram M, Abad V, Arango A, García J, Shoenfeld Y. Anti‐infectious antibodies and autoimmune‐associated autoantibodies in patients with type I diabetes mellitus and their close family members. Annals of the New York Academy of Sciences. 2009;1173(1):633-9.
40. Molan A-L, Ismail M. Study the possible association between toxoplasmosis and diabetes mellitus in IRAQ. World Journal of Pharmacy and Pharmaceutical Sciences. 2016;6(3):85-96.
41. Nosaka, Kazunori, Michael Hunter, and Wei Wang. The role of Toxoplasma gondii as a possible inflammatory agent in the pathogenesis of type 2 diabetes mellitus in humans. Family Medicine and Community Health 4.4 (2016): 44-62